171 related articles for article (PubMed ID: 22364398)
1. Combinatorial use of bone morphogenetic protein 6, noggin and SOST significantly predicts cancer progression.
Yuen HF; McCrudden CM; Grills C; Zhang SD; Huang YH; Chan KK; Chan YP; Wong ML; Law S; Srivastava G; Fennell DA; Dickson G; El-Tanani M; Chan KW
Cancer Sci; 2012 Jun; 103(6):1145-54. PubMed ID: 22364398
[TBL] [Abstract][Full Text] [Related]
2. The prognostic significance of BMP-6 signaling in prostate cancer.
Yuen HF; Chan YP; Cheung WL; Wong YC; Wang X; Chan KW
Mod Pathol; 2008 Dec; 21(12):1436-43. PubMed ID: 18931653
[TBL] [Abstract][Full Text] [Related]
3. BMP signaling pathways affect differently migration and invasion of esophageal squamous cancer cells.
Hu M; Cui F; Liu F; Wang J; Wei X; Li Y
Int J Oncol; 2017 Jan; 50(1):193-202. PubMed ID: 27959431
[TBL] [Abstract][Full Text] [Related]
4. Exploration of Shh and BMP paracrine signaling in a prostate cancer xenograft.
Shaw A; Gipp J; Bushman W
Differentiation; 2010 Jan; 79(1):41-7. PubMed ID: 19773112
[TBL] [Abstract][Full Text] [Related]
5. Expression, regulation and clinical significance of bone morphogenetic protein 6 in esophageal squamous-cell carcinoma.
Raida M; Sarbia M; Clement JH; Adam S; Gabbert HE; Höffken K
Int J Cancer; 1999 Sep; 83(1):38-44. PubMed ID: 10449605
[TBL] [Abstract][Full Text] [Related]
6. Spaciotemporal association and bone morphogenetic protein regulation of sclerostin and osterix expression during embryonic osteogenesis.
Ohyama Y; Nifuji A; Maeda Y; Amagasa T; Noda M
Endocrinology; 2004 Oct; 145(10):4685-92. PubMed ID: 15217980
[TBL] [Abstract][Full Text] [Related]
7. Contextual effect of repression of bone morphogenetic protein activity in prostate cancer.
Pham LK; Liang M; Adisetiyo HA; Liao CP; Cohen MB; Tahara SM; Frenkel B; Kasahara N; Roy-Burman P
Endocr Relat Cancer; 2013 Dec; 20(6):861-74. PubMed ID: 24042462
[TBL] [Abstract][Full Text] [Related]
8. Bone morphogenetic protein (BMP)-6 signaling and BMP antagonist noggin in prostate cancer.
Haudenschild DR; Palmer SM; Moseley TA; You Z; Reddi AH
Cancer Res; 2004 Nov; 64(22):8276-84. PubMed ID: 15548695
[TBL] [Abstract][Full Text] [Related]
9. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.
Feeley BT; Gamradt SC; Hsu WK; Liu N; Krenek L; Robbins P; Huard J; Lieberman JR
J Bone Miner Res; 2005 Dec; 20(12):2189-99. PubMed ID: 16294272
[TBL] [Abstract][Full Text] [Related]
10. Unique regulation of SOST, the sclerosteosis gene, by BMPs and steroid hormones in human osteoblasts.
Sutherland MK; Geoghegan JC; Yu C; Winkler DG; Latham JA
Bone; 2004 Aug; 35(2):448-54. PubMed ID: 15268896
[TBL] [Abstract][Full Text] [Related]
11. BMP system expression in GCs from polycystic ovary syndrome women and the in vitro effects of BMP4, BMP6, and BMP7 on GC steroidogenesis.
Khalaf M; Morera J; Bourret A; Reznik Y; Denoual C; Herlicoviez M; Mittre H; Benhaim A
Eur J Endocrinol; 2013 Mar; 168(3):437-44. PubMed ID: 23243014
[TBL] [Abstract][Full Text] [Related]
12. Identification of a key residue mediating bone morphogenetic protein (BMP)-6 resistance to noggin inhibition allows for engineered BMPs with superior agonist activity.
Song K; Krause C; Shi S; Patterson M; Suto R; Grgurevic L; Vukicevic S; van Dinther M; Falb D; Ten Dijke P; Alaoui-Ismaili MH
J Biol Chem; 2010 Apr; 285(16):12169-80. PubMed ID: 20048150
[TBL] [Abstract][Full Text] [Related]
13. Identification of liver-derived bone morphogenetic protein (BMP)-9 as a potential new candidate for treatment of colorectal cancer.
Cai C; Itzel T; Gaitantzi H; de la Torre C; Birgin E; Betge J; Gretz N; Teufel A; Rahbari NN; Ebert MP; Breitkopf-Heinlein K
J Cell Mol Med; 2022 Jan; 26(2):343-353. PubMed ID: 34841646
[TBL] [Abstract][Full Text] [Related]
14. RNA interference for noggin enhances the biological activity of bone morphogenetic proteins in vivo and in vitro.
Takayama K; Suzuki A; Manaka T; Taguchi S; Hashimoto Y; Imai Y; Wakitani S; Takaoka K
J Bone Miner Metab; 2009; 27(4):402-11. PubMed ID: 19252814
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of bone morphogenetic protein 6 (BMP6) expression, clinical and pathological factors in clinically node-negative oral squamous cell carcinoma (OSCC).
Suton P; Bolanca A; Grgurevic L; Erjavec I; Nikles I; Muller D; Manojlovic S; Vukicevic S; Petrovecki M; Dokuzovic S; Luksic I
J Craniomaxillofac Surg; 2019 Jan; 47(1):80-86. PubMed ID: 30503606
[TBL] [Abstract][Full Text] [Related]
16. Wnt inhibitors Dkk1 and Sost are downstream targets of BMP signaling through the type IA receptor (BMPRIA) in osteoblasts.
Kamiya N; Kobayashi T; Mochida Y; Yu PB; Yamauchi M; Kronenberg HM; Mishina Y
J Bone Miner Res; 2010 Feb; 25(2):200-10. PubMed ID: 19874086
[TBL] [Abstract][Full Text] [Related]
17. Noggin and sclerostin bone morphogenetic protein antagonists form a mutually inhibitory complex.
Winkler DG; Yu C; Geoghegan JC; Ojala EW; Skonier JE; Shpektor D; Sutherland MK; Latham JA
J Biol Chem; 2004 Aug; 279(35):36293-8. PubMed ID: 15199066
[TBL] [Abstract][Full Text] [Related]
18. Expression of BMP6 is associated with its methylation status in colorectal cancer tissue but lacks prognostic significance.
Sangplod P; Kanngurn S; Boonpipattanapong T; Ruangrat P; Sangkhathat S
Asian Pac J Cancer Prev; 2014; 15(17):7091-5. PubMed ID: 25227796
[TBL] [Abstract][Full Text] [Related]
19. Surface-mediated delivery of siRNA from fibrin hydrogels for knockdown of the BMP-2 binding antagonist noggin.
Kowalczewski CJ; Saul JM
Acta Biomater; 2015 Oct; 25():109-20. PubMed ID: 26234488
[TBL] [Abstract][Full Text] [Related]
20. Coordinated expression of noggin and bone morphogenetic proteins (BMPs) during early skeletogenesis and induction of noggin expression by BMP-7.
Nifuji A; Noda M
J Bone Miner Res; 1999 Dec; 14(12):2057-66. PubMed ID: 10620065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
